Table 3 Meta-analysis of the effect of statins on renal outcomes in diabetes

1. Overall

10

175/176

0.22

24

−0.46(−0.68,–0.25)

z = 4.21,p_z < 0.0001

 Caucasian

6

71/71

0.12

43

−0.41(−0.75,–0.07)

z = 2.36,p_z = 0.02

 Asian

4

104/105

0.41

0

−0.50(−0.77,–0.22)

z = 3.51,p_z = 0.0004

 T1DM

2

31/29

0.96

0

−0.01(−0.52,0.50)

z = 0.04,p_z = 0.97

 T2DM

8

144/147

0.31

14

−0.56(−0.80,–0.32)

z = 4.63,p_z < 0.00001

  < 30 mg/d

2

31/33

0.14

53

−0.29(−0.78,0.21)

z = 1.12,p_z = 0.26

 30-299 mg/d

4

58/59

0.21

33

−0.71(−1.09,–0.33)

z = 3.65,p_z = 0.0003

  ≥ 300 mg/d

4

86/84

0.42

0

−0.37(−0.67,–0.06)

z = 2.37,p_z = 0.02

  < 1 year

6

118/116

0.50

0

−0.41(−0.67,–0.15)

z = 3.09,p_z = 0.002

 1 ~ 3 years

4

57/60

0.07

58

−0.57(−0.95,–0.19)

z = 2.94,p_z = 0.003

 low-intensity statins

3

61/63

0.18

41

−0.48(−0.84,–0.12)

z = 2.61,p_z = 0.009

 moderate-intensity statins

2

20/19

0.27

16

−0.35(−0.99,0.30)

z = 1.05,p_z = 0.29

 high-intensity statins

5

94/94

0.13

44

−0.47(−0.77,–0.18)

z = 3.15,p_z = 0.002

1. Overall

6

1252/1257

0.73

0

0.49(−0.06,1.03)

z = 1.75,p_z = 0.08

 Caucasian

5

1184/1187

0.48

0

0.48(−0.08,1.04)

z = 1.69,p_z = 0.09

 Asian

1

68/70

0.75

0

0.64(−1.87,3.15)

z = 0.50,p_z = 0.62

 T1DM

1

12/9

−3.00(−17.22,11.22)

z = 0.41,p_z = 0.68

 T2DM

5

1240/1248

0.64

0

0.49(−0.05,1.04)

z = 1.77,p_z = 0.08

  < 30 mg/d

1

913/918

0.34(−0.28,0.96)

z = 1.08,p_z = 0.28

 30-299 mg/d

4

311/312

0.52

0

1.03(−0.16,2.21)

z = 1.70,p_z = 0.09

  ≥ 300 mg/d

1

28/27

0.56

0

0.73(−6.15,7.61)

z = 0.21,p_z = 0.83

 with ACEI or ARB

4

1218/1220

0.74

0

0.04(−0.04,0.12)

z = 0.89,p_z = 0.37

 without ACEI or ARB

2

18/20

0.94

0

1.14(0.44,1.84)

z = 3.20,p_z = 0.001

  < 1 year

3

72/71

0.47

0

0.69(−1.85,3.24)

z = 0.53,p_z = 0.59

 1 ~ 3 years

3

1180/1186

0.56

0

0.48(−0.08,1.04)

z = 1.68,p_z = 0.09

 low-intensity statins

3

1206/1211

0.81

0

0.42(−0.13,0.98)

z = 1.51,p_z = 0.13

 moderate-intensity statins

2

20/19

0.27

19

3.07(−6.28,12.43)

z = 0.64,p_z = 0.52

 high-intensity statins

1

26/27

0.80

0

2.76(−0.83,6.36)

z = 1.51,p_z = 0.13

 60 ~ 89 ml/min/1.73 m²

4

1234/1238

0.94

0

0.43(−0.12,0.98)

z = 1.52,p_z = 0.13

  > =90 ml/min/1.73 m²

2

18/19

0.48

0

3.45(−0.40,7.30)

z = 1.76,p_z = 0.08

1. Overall

5

99/100

<0.00001

93

−1.68(−3.23,–0.12)

z = 2.12,p_z = 0.03

 Caucasian

2

18/20

<0.00001

96

−25.99(−78.54,26.57)

z = 0.97,p_z = 0.33

 Asian

3

81/80

0.0001

89

−1.78(−2.98,–0.57)

z = 2.88,p_z = 0.004

 30-299 mg/d

4

67/69

<0.00001

94

−2.17(−4.56,0.23)

z = 1.77,p_z = 0.08

  ≥ 300 mg/d

1

32/31

−1.12(−1.65, −0.58)

z = 4.11,p_z < 0.0001

  < 1 year

4

89/90

<0.00001

95

−1.90(−3.91,0.11)

z = 1.85,p_z = 0.06

 1 ~ 3 years

1

10/10

−1.29(−2.28,–0.31)

z = 2.58,p_z = 0.010

 low-intensity statins

1

10/10

−1.29(−2.28,–0.31)

z = 2.58,p_z = 0.010

 moderate-intensity statins

1

8/10

−53.77(−73.67,–33.88)

z = 5.30,p_z < 0.00001

 high-intensity statins

3

81/80

<0.00001

93

−1.39(−2.87,0.09)

z = 1.84,p_z = 0.07

1. Overall

4

127/126

<0.00001

95

0.75(−0.52,2.03)

z = 1.15,p_z = 0.25

 30-299 mg/d

2

69/69

<0.00001

98

1.62(−1.91,5.15)

z = 0.90,p_z = 0.37

  ≥ 300 mg/d

2

58/57

0.93

0

−0.05(−0.42,0.31)

z = 0.28,p_z = 0.78

 low-intensity statins

1

30/30

3.44(2.62,4.25)

z = 0.00,p_z = 1.00

 high-intensity statins

3

97/96

0.93

0

−0.10(−0.38,0.19)

z = 0.98,p_z = 0.33

1.Overall

2

51/52

0.88

0

−0.26(−0.64,0.13)

z = 1.29,p_z = 0.20